Abstract | PURPOSE: MATERIALS AND METHODS: In this single-arm, phase II, multi-institutional study, 92 patients with biopsy-confirmed HCC or ICC, determined to be unresectable by multidisciplinary review, with a Child-Turcotte-Pugh score ( CTP) of A or B, ECOG performance status of 0 to 2, no extrahepatic disease, and no prior radiation received 15 fractions of proton therapy to a maximum total dose of 67.5 Gy equivalent. Sample size was calculated to demonstrate > 80% local control (LC) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria at 2 years for HCC patients, with the parallel goal of obtaining acceptable precision for estimating outcomes for ICC. RESULTS: Eighty-three patients were evaluable: 44 with HCC, 37 with ICC, and two with mixed HCC/ICC. The CTP score was A for 79.5% of patients and B for 15.7%; 4.8% of patients had no cirrhosis. Prior treatment had been given to 31.8% of HCC patients and 61.5% of ICC patients. The median maximum dimension was 5.0 cm (range, 1.9 to 12.0 cm) for HCC patients and 6.0 cm (range, 2.2 to 10.9 cm) for ICC patients. Multiple tumors were present in 27.3% of HCC patients and in 12.8% of ICC patients. Tumor vascular thrombosis was present in 29.5% of HCC patients and in 28.2% of ICC patients. The median dose delivered to both HCC and ICC patients was 58.0 Gy. With a median follow-up among survivors of 19.5 months, the LC rate at 2 years was 94.8% for HCC and 94.1% for ICC. The overall survival rate at 2 years was 63.2% for HCC and 46.5% ICC. CONCLUSION: High-dose hypofractionated proton therapy demonstrated high LC rates for HCC and ICC safely, supporting ongoing phase III trials of radiation in HCC and ICC.
|
Authors | Theodore S Hong, Jennifer Y Wo, Beow Y Yeap, Edgar Ben-Josef, Erin I McDonnell, Lawrence S Blaszkowsky, Eunice L Kwak, Jill N Allen, Jeffrey W Clark, Lipika Goyal, Janet E Murphy, Milind M Javle, John A Wolfgang, Lorraine C Drapek, Ronald S Arellano, Harvey J Mamon, John T Mullen, Sam S Yoon, Kenneth K Tanabe, Cristina R Ferrone, David P Ryan, Thomas F DeLaney, Christopher H Crane, Andrew X Zhu |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 34
Issue 5
Pg. 460-8
(Feb 10 2016)
ISSN: 1527-7755 [Electronic] United States |
PMID | 26668346
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural)
|
Copyright | © 2015 by American Society of Clinical Oncology. |
Topics |
- Adult
- Aged
- Aged, 80 and over
- Bile Duct Neoplasms
(mortality, pathology, radiotherapy)
- Carcinoma, Hepatocellular
(mortality, pathology, radiotherapy)
- Cholangiocarcinoma
(mortality, pathology, radiotherapy)
- Female
- Follow-Up Studies
- Humans
- Liver Neoplasms
(mortality, pathology, radiotherapy)
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Prospective Studies
- Proton Therapy
- Radiation Dose Hypofractionation
- Survival Rate
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|